The DOI matches its Crossref record; 55 of the 55 references it cites were found in a registry or an index.
Sodium-glucose transporter 2 is a diagnostic and therapeutic target for early-stage lung adenocarcinoma
Open accessAbstract
Lung premalignancy and early-stage adenocarcinoma use a mechanism of glucose transport that can be targeted for early diagnosis and treatment.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“In atypical adenomatous hyperplasias (AAHs) of the lung, premalignant lesions overexpress sodium-dependent glucose transporter 2 (SGLT2).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [24]
In the citing paper
“But an alternative tracer, methyl-4-deoxy-4-[18F]-fluoro-α-d-glucopyranoside (Me4FDG), is taken up by SGLT and can identify AAH and low-grade adenocarcinomas of the lung (24).”
From Metabolic reprogramming and cancer progression (2020) · cites this paper as [24]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Longitudinal data analysis using generalized linear models
LIANG, K.-Y., & ZEGER, S. L. (1986) · Biometrika · doi:10.1093/biomet/73.1.13 · Cited by 18,550
Understanding the Warburg Effect: The Metabolic Requirements of Cell Proliferation
Vander Heiden, M. G., Cantley, L. C., & Thompson, C. B. (2009) · Science · doi:10.1126/science.1160809 · Cited by 16,197
Warburg, O. (1956) · Science · doi:10.1126/science.123.3191.309 · Cited by 13,425
Reduced Lung-Cancer Mortality with Low-Dose Computed Tomographic Screening
The National Lung Screening Trial Research Team (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1102873 · Cited by 11,064
The 2015 World Health Organization Classification of Lung Tumors
Travis, W. D., Brambilla, E. M., Nicholson, A. G., Yatabe, Y., Austin, J. H. M., Beasley, M. B., Chirieac, L. R., Đačić, S., Duhig, E., Flieder, D. B., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000630 · Cited by 4,532
Benefits and Harms of CT Screening for Lung Cancer
Bach, P. B., Mirkin, J. N., Oliver, T. K., Azzoli, C. G., Berry, D. A., Brawley, O. W., Byers, T., Colditz, G. A., Gould, M. K., Jett, J. R., et al. (2012) · JAMA · doi:10.1001/jama.2012.5521 · Cited by 1,237
Oxygen sensing and molecular adaptation to hypoxia
Bunn, H. F., & Poyton, R. Ο. (1996) · Physiological Reviews · doi:10.1152/physrev.1996.76.3.839 · Cited by 1,185
AMIDE: A Free Software Tool for Multimodality Medical Image Analysis
Loening, A. M., & Gambhir, S. S. (2003) · Molecular Imaging · doi:10.1162/153535003322556877 · Cited by 967
Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., & List, J. F. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60407-2 · Cited by 873
Regulation of glut1 mRNA by Hypoxia-inducible Factor-1
Chen, C., Pore, N., Behrooz, A., Ismail‐Beigi, F., & Maity, A. M. (2001) · Journal of Biological Chemistry · doi:10.1074/jbc.m010144200 · Cited by 769
Research works printed but not linked: 1
- L. C. Horn L D. H. Johnson Neoplasms of the Lung in Harrison’s Principles of Internal Medicine D. Kasper A. Fauci S. Hauser D. Longo J. Jameson J. Loscalzo Eds. (McGraw-Hill ed. 19 2015); http://accessmedicine.mhmedical.com/content.aspx?bookid=1130&Sectionid=69857702.
Cited by
Sorted by citations
Metabolic reprogramming and cancer progression
Faubert, B., Solmonson, A., & DeBerardinis, R. J. (2020) · Science · doi:10.1126/science.aaw5473 · Cited by 2,740
Mitochondrial Metabolism as a Target for Cancer Therapy
Vasan, K., Werner, M., & Chandel, N. S. (2020) · Cell Metabolism · doi:10.1016/j.cmet.2020.06.019 · Cited by 762
Li, J., Liu, H., Takagi, S., Nitta, K., Kitada, M., Srivastava, S. P., Takagaki, Y., Kanasaki, K., & Koya, D. (2020) · JCI Insight · doi:10.1172/jci.insight.129034 · Cited by 246
Glucose Transporters as a Target for Anticancer Therapy
Pliszka, M., & Szablewski, L. (2021) · Cancers · doi:10.3390/cancers13164184 · Cited by 214
Gongora, C. A., Drobni, Z. D., Silva, T. Q. A. C., Zafar, A., Gong, J., Zlotoff, D. A., Gilman, H. K., Hartmann, S. E., Sama, S., Nikolaidou, S., et al. (2022) · JACC Heart Failure · doi:10.1016/j.jchf.2022.03.006 · Cited by 161
Wang, J., Yang, Y., Shao, F., Meng, Y., Guo, D. S., He, J., & Lu, Z. (2024) · Nature Metabolism · doi:10.1038/s42255-024-01037-4 · Cited by 144
Emergence of SGLT2 Inhibitors as Powerful Antioxidants in Human Diseases
Tsai, K., Chen, Y., Chiou, T. T., Chu, T., Li, L., Ng, H., Lee, W., & Lee, C. (2021) · Antioxidants · doi:10.3390/antiox10081166 · Cited by 140
SGLT-2 Inhibitors in Cancer Treatment—Mechanisms of Action and Emerging New Perspectives
Dutka, M., Bobiński, R., Francuz, T., Garczorz, W., Zimmer, K., Ilczak, T. P., Ćwiertnia, M., & Hajduga, M. B. (2022) · Cancers · doi:10.3390/cancers14235811 · Cited by 139
Evolutionary metabolic landscape from preneoplasia to invasive lung adenocarcinoma
Nie, M., Yao, K., Zhu, X., Chen, N., Xiao, N., Wang, Y., Peng, B., Yao, L., Li, P., Zhang, P., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-26685-y · Cited by 130
Heerspink, H. J. L., Sjöström, C. D., Jongs, N., Chertow, G. M., Kosiborod, M., Hou, F. F., McMurray, J. J. V., Rossing, P. R., Correa‐Rotter, R., Kurlyandskaya, R., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab094 · Cited by 121
SGLT2 inhibition slows tumor growth in mice by reversing hyperinsulinemia
Nasiri, A. R., Rodrigues, M. R. D. S., Li, Z., Leitner, B. P., & Perry, R. J. (2019) · Cancer & Metabolism · doi:10.1186/s40170-019-0203-1 · Cited by 116
Perry, R. J., & Shulman, G. I. (2020) · Journal of Biological Chemistry · doi:10.1074/jbc.rev120.008387 · Cited by 121
The Cardioprotective and Anticancer Effects of SGLT2 Inhibitors
Dabour, M. S., George, M. Y., DANIEL, M. R., Blaes, A. H., & Zordoky, B. N. M. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.01.007 · Cited by 119
Hoong, C. W. S., & Chua, M. W. J. (2021) · Endocrinology · doi:10.1210/endocr/bqab079 · Cited by 112
Sodium-Glucose Cotransporter-2 (SGLT2) Inhibitors: A Clinician’s Guide
Simes, B. C., & MacGregor, G. G. (2019) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s212003 · Cited by 103
p63 and SOX2 Dictate Glucose Reliance and Metabolic Vulnerabilities in Squamous Cell Carcinomas
Hsieh, M.-H., Choe, J. H., Gadhvi, J. G., Kim, Y. J., Arguez, M. A., Palmer, M., Gerold, H., Nowak, C. M., Do, H., Mazambani, S., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.07.027 · Cited by 93
Self-citationCardiovascular Disease and Cancer: Is There Increasing Overlap?
Vincent, L. L., Leedy, D. J., Masri, S. C., & Cheng, R. K.-H. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0796-0 · Cited by 88
Canagliflozin primes antitumor immunity by triggering PD-L1 degradation in endocytic recycling
Ding, L., Chen, X., Zhang, W., Dai, X., Guo, H., Pan, X., Xu, Y., Feng, J., Yuan, M., Gao, X., et al. (2023) · Journal of Clinical Investigation · doi:10.1172/jci154754 · Cited by 84
Sodium-glucose cotransporter 2 (SGLT2) inhibitors and non-small cell lung cancer survival
Luo, J., HENDRYX, M. S., & Dong, Y. (2023) · British Journal of Cancer · doi:10.1038/s41416-023-02177-2 · Cited by 82
A new classification of cardio-oncology syndromes
de Boer, R. A., Aboumsallem, J. P., Bračun, V., Leedy, D. J., Cheng, R. K.-H., Patel, S., Rayan, D., Zaharova, S., Rymer, J. A., Kwan, J. M., et al. (2021) · Cardio-Oncology · doi:10.1186/s40959-021-00110-1 · Cited by 71
Unlocking the Full Potential of SGLT2 Inhibitors: Expanding Applications beyond Glycemic Control
Youssef, M. E., Yahya, G., Popoviciu, M. S., Cavalu, S. D., Abdel-Dayem, M. A., & Saber, S. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24076039 · Cited by 72
Ren, D., Sun, Y., Zhang, D., Li, D., Liu, Z., Jin, X., & Wu, H. (2021) · Cancer Letters · doi:10.1016/j.canlet.2021.07.035 · Cited by 65
Sodium-glucose cotransporter 2 (SGLT2) inhibitor initiation and hepatocellular carcinoma prognosis
HENDRYX, M. S., Dong, Y., Ndeke, J. M., & Luo, J. (2022) · PLoS ONE · doi:10.1371/journal.pone.0274519 · Cited by 67
Chen, H., Kim, A. W., Hsin, M. K. Y., Shrager, J. B., Prosper, A. E., Wahidi, M. M., Wigle, D. A., Wu, C. C., Huang, J. G., Yasufuku, K., et al. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.02.026 · Cited by 64
Self-citationCanagliflozin Inhibits Human Endothelial Cell Proliferation and Tube Formation
Behnammanesh, G., Durante, Z. E., Peyton, K. J., Martinez-Lemus, L. A., Brown, S. M., Bender, S. B., & Durante, W. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00362 · Cited by 61
Chiang, C., Chiang, C.-H., Chiang, C., Sheng‐Kai, K., Peng, C.-Y., Hsia, Y. P., Horng, C., Chen, C.-Y., Chang, Y.-C., See, X. Y., et al. (2022) · Heart · doi:10.1136/heartjnl-2022-321545 · Cited by 63
Interindividual Heterogeneity of SGLT2 Expression and Function in Human Pancreatic Islets
Saponaro, C., Mühlemann, M., Acosta-Montalvo, A., Piron, A., Gmyr, V., Delalleau, N., Moerman, E., Thévenet, J., Pasquetti, G., Coddeville, A., et al. (2020) · Diabetes · doi:10.2337/db19-0888 · Cited by 57
Repurposing sodium-glucose co-transporter 2 inhibitors (SGLT2i) for cancer treatment – A Review
Lau, K. T. K., Ng, L., Wong, J. W. H., Loong, H. H.-F., Chan, W., Lee, C., & Wong, C. K. H. (2021) · Reviews in Endocrine and Metabolic Disorders · doi:10.1007/s11154-021-09675-9 · Cited by 55
Spiazzi, B. F., Naibo, R. A., Wayerbacher, L. F., Piccoli, G. F., Farenzena, L. P., Londero, T. M., da Natividade, G. R., Zoldan, M., Degobi, N. A. H., Niches, M. D. S., et al. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110621 · Cited by 59
Bhatti, A. W., Patel, R. P., Dani, S. S., Khadke, S., Makwana, B., Lessey, C., Shah, J. R., Husami, Z., Yang, E. H., Thavendiranathan, P., et al. (2024) · JACC CardioOncology · doi:10.1016/j.jaccao.2024.08.001 · Cited by 55
Self-citationPerturbations of cancer cell metabolism by the antidiabetic drug canagliflozin
Papadopoli, D. J., Uchenunu, O., Palia, R., Chekkal, N., Hulea, L., Topisirović, I., Pollak, M., & St‐Pierre, J. (2021) · Neoplasia · doi:10.1016/j.neo.2021.02.003 · Cited by 54
Exploiting metabolic vulnerabilities of Non small cell lung carcinoma
Majem, B., Nadal, E., & Muñoz‐Pinedo, C. (2019) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2019.06.004 · Cited by 57
Glucose transporters as markers of diagnosis and prognosis in cancer diseases
Szablewski, L. (2022) · Oncology Reviews · doi:10.4081/oncol.2022.561 · Cited by 53
Metabolic Regulation of Epigenetic Modifications and Cell Differentiation in Cancer
Saggese, P., Sellitto, A., Martinez, C. A., Giurato, G., Nassa, G., Rizzo, F. M., Tarallo, R., & Scafoglio, C. (2020) · Cancers · doi:10.3390/cancers12123788 · Cited by 46
Self-citationZhou, R. W., Xu, J., Martin, T. C., Zachem, A. L., He, C., Ozturk, S., Demircioğlu, D., Bansal, A., Trotta, A. P., Giotti, B., et al. (2022) · Nature Communications · doi:10.1038/s41467-022-33377-8 · Cited by 49
Therapeutic Targeting of SGLT2: A New Era in the Treatment of Diabetes and Diabetic Kidney Disease
Shaffner, J., Chen, B., Malhotra, D. K., Dworkin, L. D., & Gong, R. (2021) · Frontiers in Endocrinology · doi:10.3389/fendo.2021.749010 · Cited by 48
Nutrient transporters: connecting cancer metabolism to therapeutic opportunities
Nwosu, Z. C., Song, M. G., di Magliano, M. P., Lyssiotis, C. A., & Kim, S. E. (2023) · Oncogene · doi:10.1038/s41388-023-02593-x · Cited by 51
The Metabolic Interplay between Cancer and Other Diseases
Le, A., Udupa, S., & Zhang, C. (2019) · Trends in cancer · doi:10.1016/j.trecan.2019.10.012 · Cited by 48
Yamamoto, L., Yamashita, S.-I., Nomiyama, T., Kawanami, T., Hamaguchi, Y., Shigeoka, T., Horikawa, T., Tanaka, Y., Yanase, T., Kawanami, D., et al. (2021) · Diabetology International · doi:10.1007/s13340-021-00494-6 · Cited by 45
Does 2-FDG PET Accurately Reflect Quantitative In Vivo Glucose Utilization?
Barrio, J. R., Huang, S., Satyamurthy, N., Scafoglio, C., Yu, A. S., Alavi, A. A., & Krohn, K. A. (2019) · Journal of Nuclear Medicine · doi:10.2967/jnumed.119.237446 · Cited by 45
Self-citationOkada, J., Yamada, E., Saito, T., Yokoo, H., Osaki, A., Shimoda, Y., Ozawa, A., Nakajima, Y., Pessin, J., Okada, S., et al. (2020) · Molecules · doi:10.3390/molecules25030495 · Cited by 40
Glucose Deprivation Promotes Pseudohypoxia and Dedifferentiation in Lung Adenocarcinoma
Saggese, P., Pandey, A., Alcaraz, M., Fung, E., Hall, A., Yanagawa, J., Rodriguez, E. F., Grogan, T., Giurato, G., Nassa, G., et al. (2023) · Cancer Research · doi:10.1158/0008-5472.can-23-1148 · Cited by 44
Self-citationChen, L., Liu, K., Zhao, X., Shen, H., Zhao, K., & Zhu, W. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.759897 · Cited by 39
Chen, P., Rojas, F. R., Hu, X., Serrano, A. G., Zhu, B., Chen, H., Hong, L., Bandyoyadhyay, R., Aminu, M., Kalhor, N., et al. (2023) · Modern Pathology · doi:10.1016/j.modpat.2023.100326 · Cited by 35
Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities
Pandey, A., Alcaraz, M., Saggese, P., Soto, A., Gomez, E., Jaldu, S., Yanagawa, J., & Scafoglio, C. (2025) · Cancers · doi:10.3390/cancers17030466 · Cited by 35
Self-citationWang, L., Liu, M., Yin, F., Wang, Y., Li, X., Wu, Y., Ye, C., & Liu, J. (2019) · Molecules · doi:10.3390/molecules24183390 · Cited by 34
Self-citationRepurposing SGLT2 Inhibitors for Neurological Disorders: A Focus on the Autism Spectrum Disorder
Nakhal, M. M., Aburuz, S., Sadek, B. S., & Akour, A. A. (2022) · Molecules · doi:10.3390/molecules27217174 · Cited by 33
Heterogeneity of Glucose Transport in Lung Cancer
Martinez, C. A., & Scafoglio, C. (2020) · Biomolecules · doi:10.3390/biom10060868 · Cited by 35
Self-citationSGLT-2i and Risk of Malignancy in Type 2 Diabetes: A Meta-Analysis of Randomized Controlled Trials
Shi, N., Shi, Y., Xu, J., Si, Y.-X., Yang, T., Zhang, M., Ng, D. M., Li, X., & Xie, F. (2021) · Frontiers in Public Health · doi:10.3389/fpubh.2021.668368 · Cited by 35
Dong, S., Zhang, M., Cheng, Z., Zhang, X., Liang, W., Li, S., Li, L., Xu, Q., Song, S., Liu, Z., et al. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103207 · Cited by 36
Sodium-glucose co-transporter-2 inhibitors in patients treated with immune checkpoint inhibitors
Perelman, M. G., Brzezinski, R. Y., Waissengrin, B., Leshem, Y., Bainhoren, O., Rubinstein, T. A., Perelman, M., Rozenbaum, Z., Havakuk, O., Topilsky, Y., et al. (2024) · Cardio-Oncology · doi:10.1186/s40959-023-00199-6 · Cited by 32
Combined deletion of Glut1 and Glut3 impairs lung adenocarcinoma growth
Contat, C., Ancey, P., Zangger, N., Sabatino, S., Pascual, J., Escrig, S., Jensen, L. H. S., Goepfert, C., Lanz, B., Lepore, M. G., et al. (2020) · eLife · doi:10.7554/elife.53618 · Cited by 30
Solitary pulmonary nodule imaging approaches and the role of optical fibre-based technologies
Fernandes, S. E., Williams, G. O. S., Williams, E., Ehrlich, K., Stone, J. M., Finlayson, N., Bradley, M., Thomson, R. R., Akram, A. R., & Dhaliwal, K. (2020) · European Respiratory Journal · doi:10.1183/13993003.02537-2020 · Cited by 30
Park, L. K., Lim, K., Volkman, J. L., Abdiannia, M., Johnston, H., Nigogosyan, Z., Siegel, M. J., McGill, J. B., McKee, A. M., Salam, M., et al. (2023) · Cancer & Metabolism · doi:10.1186/s40170-023-00306-2 · Cited by 30
SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells
Anastasio, C., Donisi, I., Vecchio, V. D., Colloca, A., Mele, L. L., Sardu, C., Marfella, R., Balestrieri, M. L., & D’Onofrio, N. (2024) · Cellular & Molecular Biology Letters · doi:10.1186/s11658-024-00599-1 · Cited by 29
Oh, M. S., Abascal, J. W., Rennels, A. K., Salehi‐Rad, R., Dubinett, S. M., & Liu, B. (2025) · Cancers · doi:10.3390/cancers17061027 · Cited by 33
Self-citationOzutsumi, T., Namisaki, T., Shimozato, N., Kaji, K., Tsuji, Y., Kaya, D., Fujinaga, Y., Furukawa, M., Nakanishi, K., Sato, S., et al. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21062164 · Cited by 28
Shining a light on metabolic vulnerabilities in non-small cell lung cancer
Dowling, C. M., Zhang, H., Chonghaile, T. N., & Wong, K.-K. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2020.188462 · Cited by 26
Effects of Dapagliflozin on Hospitalizations in Patients With Chronic Kidney Disease
Schechter, M., Jongs, N., Chertow, G. M., Mosenzon, O., McMurray, J. J. V., Correa‐Rotter, R., Rossing, P. R., Langkilde, A. M., Sjöström, C. D., Toto, R. D., et al. (2022) · Annals of Internal Medicine · doi:10.7326/m22-2115 · Cited by 28
Morita, M., & Kanasaki, K. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.06.005 · Cited by 24
Nakachi, S., Okamoto, S., Tamaki, K., Nomura, I., Tomihama, M., Nishi, Y., Fukushima, T., Tanaka, Y., Morishima, S., Imamura, M., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.112864 · Cited by 26
Chiang, C., Chiang, C., Hsia, Y. P., Jaroenlapnopparat, A., Horng, C., Wong, K. Y., Wang, S., Chang, Y., Chen, B. S., Luan, Y., et al. (2024) · Journal of Gastroenterology and Hepatology · doi:10.1111/jgh.16498 · Cited by 25
Moghaddam, S. J., Savai, R., Salehi‐Rad, R., Sengupta, S., Kammer, M. N., Massion, P. P., Beane, J., Ostrin, E. J., Priolo, C., Tennis, M. A., et al. (2024) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202406-1168st · Cited by 26
Self-citationExploration of Prognostic Biomarkers for Lung Adenocarcinoma Through Bioinformatics Analysis
Tu, Z., He, X., Zeng, L., Meng, D., Zhuang, R., Zhao, J., & Dai, W. (2021) · Frontiers in Genetics · doi:10.3389/fgene.2021.647521 · Cited by 23
Unveiling the anticancer effects of SGLT-2i: mechanisms and therapeutic potential
Sun, M., Sun, J., Sun, W., Li, X., Wang, Z., Sun, L., & Wang, Y. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1369352 · Cited by 23
Sodium-Glucose Co-Transporters Family: Current Evidence, Clinical Applications and Perspectives
Nevola, R., Villani, A., Imbriani, S., Alfano, M., Criscuolo, L., Beccia, D., Ruocco, R., Femine, A. D., Gragnano, F., Cozzolino, D., et al. (2023) · Frontiers in Bioscience-Landmark · doi:10.31083/j.fbl2805103 · Cited by 25
Guo, H., Zhou, C. X., Zheng, M., Zhang, J., Wu, H., He, Q., Ding, L., & Yang, B. (2024) · Pharmacological Research · doi:10.1016/j.phrs.2024.107084 · Cited by 23
Wan, S., Liu, Z., Chen, Y., Mai, Z., Jiang, M., Di, Q., & Sun, B. (2021) · Bioengineered · doi:10.1080/21655979.2021.2009422 · Cited by 20
Expanding the Use of SGLT2 Inhibitors in T2D Patients Across Clinical Settings
Cuttone, A., Cannavò, V., Abdullah, R. M. S., Fugazzotto, P., Arena, G., Brancati, S., Muscarà, A., Morace, C., Quartarone, C., Ruggeri, D., et al. (2025) · Cells · doi:10.3390/cells14090668 · Cited by 23
The expression and survival significance of sodium glucose transporters in pancreatic cancer
Du, J., Gu, J., Deng, J., Kong, L., Guo, Y., Jin, C., Bao, Y., Fu, D., & Li, J. (2022) · BMC Cancer · doi:10.1186/s12885-021-09060-4 · Cited by 18
Kuo, H., Wang, K., Chen, H.-H., Lai, Z., Lin, P., Chuang, Y., & Liu, L. Y. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01354-4 · Cited by 18
Association of SGLT2 inhibitors with incident cancer
Suzuki, Y., Kaneko, H., Okada, A., Ko, T., Jimba, T., Fujiu, K., Takeda, N., Morita, H., Komuro, J., Ieda, M., et al. (2024) · Diabetes & Metabolism · doi:10.1016/j.diabet.2024.101585 · Cited by 18
Xu, Y., Lin, L., Lv, D., Yan, S., He, S., & Ge, H. (2021) · Tissue and Cell · doi:10.1016/j.tice.2021.101535 · Cited by 18
Yu, L., Qiao, R., Xu, J., Han, B., & Zhong, R. (2021) · Life Sciences · doi:10.1016/j.lfs.2021.119022 · Cited by 16
Proteomics-based target identification of natural products affecting cancer metabolism
Muroi, M., & Osada, H. (2021) · The Journal of Antibiotics · doi:10.1038/s41429-021-00437-y · Cited by 16
Lipid Metabolic Alterations in KRAS Mutant Tumors: Unmasking New Vulnerabilities for Cancer Therapy
Saliakoura, M., & Konstantinidou, G. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24021793 · Cited by 15
Cardio-Onco-Metabolism – Metabolic vulnerabilities in cancer and the heart
Karlstaedt, A., & Taegtmeyer, H. (2022) · Journal of Molecular and Cellular Cardiology · doi:10.1016/j.yjmcc.2022.06.008 · Cited by 15
Obesity as an oncological risk factor. Literature review
Салухов, В. В., & Kadin, D. V. (2019) · Meditsinskiy sovet = Medical Council · doi:10.21518/2079-701x-2019-4-94-102 · Cited by 14
Insights Into Heart-Tumor Interactions in Heart Failure
Caller, T., Moore, K. J., Lehmann, L., Wu, S. M., & Leor, J. (2025) · Circulation Research · doi:10.1161/circresaha.124.325490 · Cited by 15
Wang, D., Bi, L., Ran, J., Zhang, L., Xiao, N., & Li, X. (2021) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2021.10756 · Cited by 13
Niu, R., Gao, J., Shao, X., Wang, J., Jiang, Z., Shi, Y., Zhang, F., Wang, Y., & Shao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.727094 · Cited by 13
Metabolic Phenotypes, Dependencies, and Adaptation in Lung CancerPreprint
DeNicola, G. M., & Shackelford, D. B. (2021) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a037838 · Cited by 13
Self-citationDapagliflozin suppressed gastric cancer growth via regulating OTUD5 mediated YAP1 deubiquitination
Ren, K., Wang, X., Ma, R., Chen, H., Min, T., Ma, Y., Xie, X., Wang, W., Deng, X., Zhou, Z., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177002 · Cited by 13
Diagnostic Potential of Serum Glycome Analysis in Lung Cancer: A Glycopattern Study
Hu, W., Ge, W., Xia, P., Chen, Y., Du, J., Hu, G., Wu, Z., Zhang, X., Yang, C., Jiang, J., et al. (2023) · Journal of Proteome Research · doi:10.1021/acs.jproteome.3c00645 · Cited by 12
Yang, Y., Zheng, D., Wu, C.-Y., Lizaso, A., Ye, J., Chuai, S., Ni, J., Xu, J.-F., & Jiang, G. (2019) · Small Methods · doi:10.1002/smtd.201900206 · Cited by 10
Correlation of Glucose Metabolism with Cancer and Intervention with Traditional Chinese Medicine
Lai, G., Wang, F., Nie, D., Lei, S., Wu, Z., Cao, J., & Tang, L.-L. (2022) · Evidence-based Complementary and Alternative Medicine · doi:10.1155/2022/2192654 · Cited by 13
Cho, Y. K., Kim, S., Kim, M., Lee, W. J., Kim, Y.-J., & Jung, C. H. (2025) · Diabetes & Metabolism · doi:10.1016/j.diabet.2025.101605 · Cited by 11
Wang, Z., Yang, L., Wang, W., Zhou, H., Chen, J., Ma, Z., Wang, X., Zhang, Q., Liu, H., Chao Hui, Z. H. O. U., et al. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01322-x · Cited by 11
Crunkhorn, S. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2018.229 · Cited by 9
Fine mapping-based multi-omics analysis interprets the gut-lung axis function of SGLT2 inhibitors
Yuan, F., Zhang, T., Jia, S., Zhao, J., Wan, B., & Liu, G. (2024) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2024.1447327 · Cited by 8
Klimek, K., Chen, X., Sasaki, T., Groener, D., Werner, R. A., & Higuchi, T. (2024) · Molecular Metabolism · doi:10.1016/j.molmet.2024.102055 · Cited by 8
Shapiro, S. B., Yin, H., Yu, O. H. Y., & Azoulay, L. (2024) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.16039 · Cited by 8
Niu, R., Wang, Y., Shao, X., Jiang, Z., Wang, J., & Shao, X. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.594693 · Cited by 8
van der Hoek, S., Antunes, I. F., Attia, K. A., Jacquet, O., Heeres, A., Bulthuis, M. L. C., Zijlma, R., Boersma, H. H., van Goor, H., Visser, T. J., et al. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.1c01269 · Cited by 8
The interaction between non-coding RNAs and SGLT2: A review
Jarosz-Popek, J., Eyileten, C., Gager, G. M., Nowak, A., Szwed, P., Wicik, Z., Palatini, J., von Lewinski, D., Sourij, H., Siller-Matula, J. M., et al. (2023) · International Journal of Cardiology · doi:10.1016/j.ijcard.2023.131419 · Cited by 8
Fusco, S. A. D., Cianfrocca, C., Bisceglia, I., Spinelli, A., Alonzo, A., Mocini, E., Gulizia, M. M., Gabrielli, D., Oliva, F. G., Imperoli, G., et al. (2022) · International Journal of Cardiology · doi:10.1016/j.ijcard.2022.06.048 · Cited by 7
The Clinical Relevance of the Expression of SGLT2 in Lung Adenocarcinoma
Iwai, S., Motono, N., Oyama, T., Shioya, A., Yamada, S., & Uramoto, H. (2024) · Oncology · doi:10.1159/000536060 · Cited by 7
Zhang, L., Xue, B., Yu, F., Yin, Y., & Jin, S. (2024) · Journal of Cancer · doi:10.7150/jca.96435 · Cited by 7
The comprehensive investigation of transcription factor AP-2 alpha in lung adenocarcinoma
Liao, H., & Lin, P. (2020) · Translational Cancer Research · doi:10.21037/tcr.2020.01.58 · Cited by 7
Niu, R., Shao, X., Shao, X., Jiang, Z., Wang, J., & Wang, Y. (2021) · Quantitative Imaging in Medicine and Surgery · doi:10.21037/qims-20-840 · Cited by 7
Metadata
- Authors
- Scafoglio, C. R., Villegas, B., Abdelhady, G., Bailey, S. T., Liu, J., Shirali, A. S., Wallace, W. D., Magyar, C. E., Grogan, T. R., Elashoff, D., Walser, T., Yanagawa, J., Aberle, D. R., Barrio, J. R., Dubinett, S. M., & Shackelford, D. B.
- Affiliations
- University of California, Los Angeles (US)
- University of North Carolina at Chapel Hill (US)
- Corresponding author
- Scafoglio, Claudio R.
- Shackelford, David B.
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2018-11-14
- Volume
- 10
- Issue
- 467
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC6428683
- OpenAlex
- W2901781577
- Cited by
- 176
- References
- 55
- Citations by year
- 2026: 22 · 2025: 21 · 2024: 35 · 2023: 17 · 2022: 22 · 2021: 29 · 2020: 15 · 2019: 14 · 2018: 1
- FWCI
- 4.46
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Funders
- American Cancer Society (130696-RSG-17-003-01-CCE)
- Tobacco-Related Disease Research Program (26IR-0009)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Metabolism, Diabetes, and Cancer
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Keywords
- SGLT2, lung adenocarcinoma, early-stage lung cancer, SGLT2 inhibitors, tumor growth inhibition, patient-derived xenografts, autochthonous mouse model, diagnostic imaging, therapeutic target
- MeSH terms
- Adenocarcinoma of Lung, Sodium-Glucose Transporter 2 Inhibitors, Aged, Aged, 80 and over, Animals, Biological Transport, Cell Differentiation, Female, Glucose, Humans, Male, Mice, Transgenic, Middle Aged, Neoplasm Staging, Precancerous Conditions, Survival Analysis, Mice, SCID, Xenograft Model Antitumor Assays, Cell Proliferation, Positron-Emission Tomography, Glucose Transporter Type 1, Sodium-Glucose Transporter 2, Molecular Targeted Therapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
